Quarterly Reports and Events - Research Report on Mettler-Toledo, Galena Biopharma, Achillion, Wright Medical, and OXiGENE

   Quarterly Reports and Events - Research Report on Mettler-Toledo, Galena
              Biopharma, Achillion, Wright Medical, and OXiGENE

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 15, 2013

NEW YORK, November 15, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Mettler-Toledo International Inc. (NYSE: MTD), Galena Biopharma, Inc. (NASDAQ:
GALE), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Wright Medical Group
Inc. (NASDAQ: WMGI), and OXiGENE, Inc. (NASDAQ: OXGN). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Mettler-Toledo International Inc. Research Report

On November 7, 2013, Mettler-Toledo International Inc. (Mettler-Toledo)
released its Q3 2013 results. Mettler-Toledo registered net sales of $591.7
million in Q3 2013, up 2.3% YoY. The Company posted net earnings of $74.3
million in Q3 2013, up 3.0% YoY. Mettler-Toledo reported diluted EPS of $2.43
in Q3 2013, up 6.6% YoY. Commenting on the results, Olivier Filliol, President
and CEO of Mettler-Toledo, said, "We saw an improvement in market conditions
in Europe while customer demand in the Americas remains solid. In China, soft
market demand, continued credit constraints in specific segments of our
customer base and the exit of certain industrial product lines resulted in a
sales decline. However, we generated good EPS growth as we benefitted from our
various margin improvement and cost control initiatives. Cash flow was also
very strong in the quarter." The Full Research Report on Mettler-Toledo
International Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/ac69_MTD

--

Galena Biopharma, Inc. Research Report

On November 6, 2013, Galena Biopharma, Inc. (Galena Biopharma) released its Q3
2013 results. The Company posted net loss of $9.3 million in Q3 2013, compared
to net loss of $6.3 million in Q3 2012. Galena Biopharma reported basic and
diluted net loss per share of $0.11 in Q3 2013, compared to basic and diluted
net loss per share of $0.09 in Q3 2012. Mark J. Ahn, Ph.D., President and CEO
of Galena Biopharma, stated, "Our commercial success to date with Abstral® has
been very encouraging and we are excited to report initial revenues ahead of
schedule. With our sales force and commercial organization fully deployed, we
continue to make significant strides with physicians, payors and patients-and
expect continuing strength with the launch." Ahn continued, "We are also
making steady progress in advancing our NeuVax™ and FBP cancer immunotherapy
pipeline." The Full Research Report on Galena Biopharma, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/cad6_GALE

--

Achillion Pharmaceuticals, Inc. Research Report

On November 12, 2013, Achillion Pharmaceuticals, Inc. (Achillion) released its
Q3 2013 results. Achillion registered net loss of $13.9 million in Q3 2013,
compared to net loss of $15.3 million in Q3 2012. The Company posted basic and
diluted net loss per share of $0.14 in Q3 2013, compared to basic and diluted
net loss per share of $0.20 in Q3 2012. Milind S. Deshpande, Ph.D., President
and CEO of Achillion, stated, "Over the next few months our priority is to
advance our proprietary assets through critical milestones, including the
completion of the preclinical work necessary to initiate first-in-human trials
with ACH-3422, our uridine-analog nucleotide prodrug, for the potential
treatment of chronic HCV." Dr. Deshpande continued, "Furthermore, we intend to
engage in regulatory discussions regarding the path forward for sovaprevir,
which remains on clinical hold, and in parallel, we plan to initiate early
next year a drug-drug interaction study followed by a therapeutic trial to
evaluate our differentiated NS5A inhibitor, ACH-3102, in combination with our
macrocyclic protease inhibitor, ACH-2684." The Full Research Report on
Achillion Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/04a2_ACHN

--

Wright Medical Group Inc. Research Report

On November 12, 2013, Wright Medical Group Inc. (Wright Medical) announced its
participation during the 25th Annual Piper Jaffray Healthcare Conference on
Tuesday, December 3, 2013, at the New York Palace Hotel in New York, New York.
The Company informed that Robert Palmisano, its President and CEO, will
present at 10:00 a.m. ET. Wright Medical reported that the live audio webcast
and replay version will be accessible through its website under the Investor
Presentations link. The Full Research Report on Wright Medical Group Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1782_WMGI

--

OXiGENE, Inc.Research Report

On November 12, 2013, OXiGENE, Inc. (OXiGENE) released its Q3 2013 results.
OXiGENE registered net loss attributable to common stock of $5.0 million in Q3
2013, compared to net loss attributable to common stock of $2.2 million in Q3
2012. OXiGENE reported basic and diluted net loss per share of $1.88 in Q3
2013, compared to basic and diluted net loss per share of $1.56 in Q3 2012.
Updating on the Company's Q3 2013 performance, OXiGENE's CEO Peter Langecker,
M.D., Ph.D., said, "During the third quarter, we focused on pursuing our lead
development programs and ensuring that we have the resources and capabilities
we need to advance our ongoing clinical and regulatory strategies, and made
progress in our earlier-stage programs. We have continued to focus on
identifying a registration pathway in the US for ZYBRESTAT® in ovarian cancer
and, at the same time, pursuing registration for ZYBRESTAT in the EU for
anaplastic thyroid cancer (ATC), utilizing the exceptional circumstances
pathway for obtaining a European marketing authorization (MAA)." The Full
Research Report on OXiGENE, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/f6ec_OXGN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.